SLC5A2 and heart failure: Rates of major adverse cardiovascular events, heart failure hospitalisation and all-cause mortality in patients with type 2 diabetes dispensed sodium glucose Cotransporter-2 inhibitors versus dipeptidyl Peptidase-4 inhibitors, stratified by frailty status.